

Patient with a rectal cancer TxN+ or T3/T4 of the mid or lower rectum treated by a neoadjuvant radiochemotherapy with 45 Gy \pm 5 Gy local + 5FU

Inclusion and exclusion criteria verification

Inclusion & Randomization

Groupe S7

Delay : 7 weeks \pm 5 days

Groupe S11

Delay : 11 weeks \pm 5 days

Interval of 7 weeks

Interval of 11 weeks

**Clinical evaluation of the response (*Rectal digital examination +/- (MRI)*)
Surgery: curative resection with total mesorectal excision**

Histological exam :

- Complete pathological response (ypT0N0)
- Quality of the mesorectum

- Mortality rate (D90) and postoperative morbidity (D90)
- R0 resection rate, sphincter conservation rate

Follow-up M1 - M3

- Stoma closure
- Adjuvant chemotherapy
- Late morbidity

Oncological Follow-up M6 - M60

- Local and distant recurrences
- Overall and disease free survival

END OF THE TRIAL